Brief: Adagene Achieves $3 Million Milestone In Collaboration With Exelixis
04/05/2023 14:12
May 4 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ACHIEVES $3 MILLION MILESTONE IN COLLABORATION
WITH
EXELIXIS FOR SUCCESSFUL NOMINATION OF SECOND SAFEBODY® NOVEL
MASKED ANTIBODY-DRUG CONJUGATE
* ADAGENE ACHIEVES $3 MILLION MILESTONE IN COLLABORATION
WITH
EXELIXIS FOR SUCCESSFUL NOMINATION OF SECOND SAFEBODY® NOVEL
MASKED ANTIBODY-DRUG CONJUGATE
Source text for Eikon: ID:nGNX76T8B6
Further company coverage: 978y.F
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate